Press Releases

May 27, 2020
Bicycle Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--May 27, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ®) technology, today announced that management will
Apr 23, 2020
Bicycle Therapeutics Appoints Zafar Qadir as General Counsel
CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 23, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced the appointment of Zafar
Apr 07, 2020
Bicycle Therapeutics Announces Pipeline Progress Update
- Phase I dose escalation completed for BT1718 — RP2D established and preliminary signs of anti-tumor activity observed, including one partial response - Dosing complete in second cohort of Phase I dose escalation for BT5528 — all doses administered in Phase I to date appear tolerable - Significant
Displaying 1 - 10 of 13